VANOBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANOBID (VANOBID).
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
| Metabolism | Vancomycin is primarily excreted unchanged by glomerular filtration, with minimal metabolism. Approximately 80-90% of an administered dose is recovered in urine within 24 hours. |
| Excretion | Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 85-92% bound to albumin. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration. |
| Bioavailability | Oral: 60-80% (first-pass metabolism reduces absolute bioavailability); Topical: 5-15% (systemic absorption depends on application site and skin integrity); Intramuscular: 90-100%. |
| Onset of Action | Oral: 1-2 hours; Topical: 2-4 hours; Intramuscular: 30-60 minutes. |
| Duration of Action | Oral: 12-18 hours; Topical: 6-12 hours (varies with formulation); Intramuscular: 12-24 hours. |
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
| Dosage form | OINTMENT |
| Renal impairment | GFR 30-50 mL/min: 500 mg every 12 hours; GFR 15-29 mL/min: 500 mg every 24 hours; GFR <15 mL/min: 500 mg every 48 hours. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%. |
| Pediatric use | 5-10 mg/kg/dose orally every 12 hours; maximum 500 mg per dose. |
| Geriatric use | Initiate at lower end of dosing range (250-500 mg every 12 hours) due to age-related renal function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANOBID (VANOBID).
| Breastfeeding | Corticosteroids are excreted in breast milk. The milk-to-plasma ratio for prednisolone is approximately 0.1-0.2. At maternal doses up to 80 mg/day prednisone equivalent, infant exposure is minimal and considered compatible with breastfeeding. However, high-dose or long-term use warrants monitoring infant for adrenal suppression. |
| Teratogenic Risk | Vanobid (corticosteroid) is classified as FDA Pregnancy Category C. In first trimester, there is potential risk of cleft palate based on animal studies; however, human data are limited. In second and third trimesters, chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm labor. Risk-benefit assessment is essential. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to vancomycin","Avoid in patients with pre-existing hearing loss unless absolutely necessary"]
| Precautions | ["Nephrotoxicity: monitor renal function and adjust dose accordingly","Ototoxicity: hearing loss may occur, especially in patients with renal impairment or those receiving high doses","Red Man Syndrome: infusion-related reaction (histamine release) can be minimized by slow infusion","Thrombophlebitis at injection site","Neutropenia","Clostridium difficile-associated diarrhea"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged therapy, assess fetal growth by ultrasound. Neonates should be monitored for adrenal insufficiency if mother received high doses near delivery. |
| Fertility Effects | Corticosteroids may delay ovulation and impair fertility by altering hypothalamic-pituitary-ovarian axis. No permanent effects on fertility documented. |